Wednesday, February 10, 2010, 2:39PM AEST - The Australian Stockmarket closes in 1 hour and 26 minutes.
To create a watchlist or portfolio of shares, Register

ACADIA Pharmaceuticals, Inc. (ACAD)

8:00AM AEST: 1.30 USD  Up 0.03 (2.36%)  
 MORE ON ACAD 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 ACADIA Pharmaceuticals Inc. (NGM:ACAD) Delayed quote dataEdit
Last Trade:1.30 USD
Trade Time: 8:00AM AEST
Change:Up 0.03 (2.36%)
Prev Close:1.27
Open:1.28
Bid:1.10 x 5000
Ask:2.20 x 100
1y Target Est:2.83
Day's Range:1.25 - 1.32
52wk Range:0.75 - 6.60
Volume:383,078
Avg Vol (3m):591,383
Market Cap:49.75M
P/E (ttm):N/A
EPS (ttm):-1.35
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add ACAD to Portfolio   Download Data

 HEADLINES 
ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 8, 2010
Business Wire (Tue, Feb 2)
ACADIA PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
EDGAR Online (Fri, Jan 29)
ACADIA PHARMACEUTICALS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Finan
EDGAR Online (Fri, Dec 18)
ACADIA PHARMACEUTICALS INC Financials
EDGAR Online Financials (Sun, Nov 15)
RHI Entertainment, Opnext: Midday Volume Plays
at TheStreet.com (Wed, Nov 11)
ACADIA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
EDGAR Online (Tue, Nov 10)
ACADIA PHARMACEUTICALS INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Change in Directors
EDGAR Online (Fri, Oct 16)
ACADIA PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
EDGAR Online (Wed, Oct 7)
Mannkind Falls on Talk of Partner, FDA Delay: BioBuzz
at TheStreet.com (Wed, Oct 7)
No Lupus Confab Invite for Immunomedics: BioBuzz
at TheStreet.com (Tue, Oct 6)
More Headlines for ACAD...

 ANALYST 
EPS Est (next year) (Dec-09) :-1.17
EPS Est (in 2 years) (Dec-10) :-0.60
Avg Rec (current)*:3.3
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
ACADIA Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices